Αποτελέσματα Αναζήτησης
26 Μαρ 2011 · Cinacalcet, the first available calcimimetic, increases the sensitivity of the calcium-sensing receptor (CaR) to circulating serum calcium, thereby safely reducing serum calcium and PTH concentrations in patients with mild-to-moderate pHPT, intractable disease, and also parathyroid carcinoma.
Cinacalcet has proved efficient in short- and long-term controls of hypercalcemia and, though bone mineral density was not improved, the available data point to cinacalcet as the treatment of choice in non-operable patients with pHPT. These results encompass a wide spectrum of disease severity.
Treatment with bisphosphonates or denosumab can raise PTH levels as a result of positive calcium signaling to the parathyroid glands in the context of inhibited bone resorption. Bisphosphonate effects may last for a
Introduction and methods. Primary hyperparathyroidism (PHPT) has evolved in its clinical presentation over the past 40 years and is now usually diagnosed at an asymptomatic stage [1]. Parathyroidectomy (PTx) is the only curative approach to this disease.
23 Μαΐ 2019 · This guideline covers diagnosing, assessing and managing primary hyperparathyroidism. It aims to improve recognition and treatment of this condition, reducing long-term complications and improving quality of life.
Primary hyperparathyroidism (pHPT) is characterized by an increase in the levels of PTH and Ca, or one of these (Ca, PTH) as a result of a dysregulation of calcium (Ca) metabolism due to inappropriate excess parathyroid hormone (PTH) autonomously produced from one or more than one parathyroid glands. Ninety to 95% of pHPT is a sporadic type ...
Parathyroidectomy is the definitive cure for primary hyperparathyroidism, and no medical therapies have been approved by the Food and Drug Administration for this disorder.
